All lobbying filings

Kaiser Foundation Health Plan Inc.

Kaiser Foundation Health Plan Inc. filed a Q1 report for Kaiser Foundation Health Plan Inc. on April 17, 2026.

Lobbying for Kaiser Foundation Health Plan Inc.

As filed: KAISER FOUNDATION HEALTH PLAN INC. for KAISER FOUNDATION HEALTH PLAN INC.

All filings by Kaiser Foundation Health Plan Inc. · Everything Kaiser Foundation Health Plan Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 17, 2026

Expenses

$2,990,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Legislation and regulation related to health care delivery and health insurance coverage, mental health and substance use disorder care and coverage and electronic health information/technology. Health coverage and issues related to H.R.7148 - Consolidated Appropriations Act, 2026 (PL 119-75) H.R.6248, S.4027 - Healthy Competition for Better Care Act S.3822, Break Up Big Medicine Act

Medicare/Medicaid

Legislation and regulation related to the Medicare and Medicare Advantage programs, as well as Medicare and Medicaid coverage, care delivery and financing. Issues related to Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4208-F3/CMS-4212-F) and 2027 Medicare Advantage and Part D Advance Notice. S. 1105, No UPCODE Act

Pharmacy

Legislation and regulation regarding pharmaceutical pricing, coverage and care; retail and inpatient pharmacy operations and the role of pharmacy benefit managers. S.1954, H.R.5526 - Biosimilar Red Tape Elimination Act S.1414 - Expedited Access to Biosimilars Act S.2780, H.R.5429 - Medication Affordability and Patent Integrity Act S. 2620 - Reforming Evergreening and Manipulation that Extends Drug Years Act (REMEDY Act) H. R. 3269 - Eliminating Thickets to Increase Competition Act (ETHIC Act)

Budget/Appropriations

Legislation and regulation related to funding, budget and appropriations. Health coverage and issues related to H.R.7148 - Consolidated Appropriations Act, 2026 (PL 119-75)

Bills named in this filing 12

H.R. 7148
Consolidated Appropriations Act, 2026
H.R. 6248
Healthy Competition for Better Care Act
S. 4027
Healthy Competition for Better Care Act
S. 3822
Break Up Big Medicine Act
S. 1105
No UPCODE Act
S. 1954
Biosimilar Red Tape Elimination Act
H.R. 5526
Biosimilar Red Tape Elimination Act
S. 1414
Expedited Access to Biosimilars Act
S. 2780
Medication Affordability and Patent Integrity Act
H.R. 5429
Medication Affordability and Patent Integrity Act
S. 2620
REMEDY Act
H.R. 3269
ETHIC Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.